COMPASS Pathways Nears Pivotal Psilocybin Data Amidst Mounting Losses

TL;DR

**CMPS is a high-risk, high-reward bet on psychedelic medicine, with Phase 3 TRD data being the make-or-break catalyst for this pre-revenue biotech.**

AI Summary

COMPASS Pathways plc, a biotechnology company, reported no revenue for the fiscal year ended December 31, 2025, continuing its trend of significant losses since inception. The company is focused on developing its investigational COMP360 psilocybin treatment, a proprietary formulation for serious mental health conditions. A key business change in 2025 was the completion of enrollment for two pivotal Phase 3 trials (COMP005 with 258 patients and COMP006 with 581 patients) evaluating COMP360 for treatment-resistant depression (TRD). The company received Breakthrough Therapy designation from the FDA for COMP360 in TRD in 2018 and published positive Phase 2b trial results in The New England Journal of Medicine in November 2022, showing a statistically significant reduction in depressive symptoms with a 25mg dose. Major risks include the need for additional financing beyond its current cash runway, potential dilution from equity sales or warrant exercises, and the inherent uncertainties and high costs of clinical drug development, particularly for central nervous system drugs. The strategic outlook centers on advancing COMP360 through Phase 3 trials for TRD and a Phase 2b/3 trial for PTSD, with an aim to accelerate commercial launch planning upon potential regulatory approval.

Why It Matters

COMPASS Pathways' progress in its Phase 3 trials for COMP360 psilocybin treatment for TRD is critical for investors, as it represents the company's sole path to potential revenue and profitability. A successful outcome could revolutionize mental health treatment, offering a novel approach for patients unresponsive to existing therapies, thereby impacting millions globally. For employees, positive trial results would secure job stability and growth in a pioneering field. However, the company's continued reliance on external financing and the highly competitive landscape, with other biotechs also exploring psychedelic-based therapies, means significant market and regulatory hurdles remain, making this a high-stakes endeavor.

Risk Assessment

Risk Level: high — COMPASS Pathways is a clinical-stage biotechnology company with no product revenue and has incurred significant losses since inception, indicating a high burn rate. The aggregate market value of ordinary shares held by non-affiliates was $257.1 million as of June 30, 2025, which, while substantial, is subject to volatility given the company's pre-commercial stage. The company explicitly states it will 'continue to need additional financing to fund our operations and capital expenditures,' highlighting a significant dependency on future capital raises, which could lead to substantial dilution for existing shareholders.

Analyst Insight

Investors should closely monitor the upcoming 26-week results from the second Phase 3 trial (COMP006) for COMP360 in TRD, as these will be a major determinant of the company's future. Given the high-risk profile and reliance on a single investigational treatment, consider this a speculative investment and allocate capital accordingly, understanding the potential for significant volatility.

Financial Highlights

debt To Equity

Not Disclosed

revenue

$0

operating Margin

Not Disclosed

total Assets

Not Disclosed

total Debt

Not Disclosed

net Income

Not Disclosed

eps

Not Disclosed

gross Margin

Not Disclosed

cash Position

Not Disclosed

revenue Growth

N/A

Revenue Breakdown

Key Numbers

• $0 — Revenue (No revenue generated for the fiscal year ended December 31, 2025, indicating pre-commercial stage.)
• 25mg — COMP360 dose (Demonstrated statistically significant efficacy in Phase 2b TRD trial.)
• 258 — Patients in COMP005 (Enrollment completed for pivotal Phase 3 TRD trial 1.)
• 581 — Patients in COMP006 (Enrollment completed for pivotal Phase 3 TRD trial 2.)
• 2018 — Year (Received FDA Breakthrough Therapy designation for COMP360 in TRD.)
• 2025 — Year (Completed enrollment for both pivotal Phase 3 TRD trials.)
• $257.1 million — Market Value (Aggregate market value of non-affiliate shares as of June 30, 2025.)
• 128,923,295 — Shares Outstanding (Common stock outstanding as of March 17, 2025.)

Key Players & Entities

• COMPASS Pathways plc (company) — registrant
• COMP360 (company) — proprietary psilocybin formulation
• U.S. Food and Drug Administration (regulator) — granted Breakthrough Therapy designation
• The New England Journal of Medicine (company) — published Phase 2b trial results
• Hercules Capital, Inc. (company) — lender in Loan Agreement
• $257.1 million (dollar_amount) — aggregate market value of non-affiliate shares as of June 30, 2025
• 128,923,295 (dollar_amount) — shares of common stock outstanding as of March 17, 2025
• COMP005 (company) — Pivotal trial 1 for TRD (n=258)
• COMP006 (company) — Pivotal trial 2 for TRD (n=581)
• $100.0 million (dollar_amount) — additional amounts available under Loan Agreement

FAQ

Risk Factors

• Need for Additional Financing [high — financial]: The company has incurred significant losses since inception and has no revenue. It will require substantial additional capital to fund its ongoing clinical trials, including the pivotal Phase 3 studies for COMP360, and for potential commercialization. Failure to secure adequate financing could jeopardize its ability to continue operations.
• Potential Dilution from Equity Issuances [medium — financial]: To fund its operations and clinical development, the company may need to raise capital through the sale of equity securities or exercise of warrants. This could result in significant dilution to existing shareholders, impacting the value of their investment.
• Clinical Drug Development Uncertainties [high — operational]: Developing new drugs, especially for central nervous system conditions like TRD and PTSD, is inherently uncertain, costly, and time-consuming. There is no guarantee that COMP360 will demonstrate sufficient safety and efficacy in ongoing Phase 3 trials to gain regulatory approval.
• Regulatory Approval Pathway [high — regulatory]: While COMP360 has received Breakthrough Therapy designation for TRD, the path to regulatory approval is rigorous. The company must successfully complete its Phase 3 trials and meet stringent FDA requirements, which can be subject to evolving scientific and regulatory standards.
• Dependence on Key Personnel [medium — operational]: The success of the company's development programs relies heavily on its management team and scientific advisors. The loss of key personnel could significantly disrupt its research and development efforts.
• Market Acceptance of Novel Treatments [medium — market]: The successful commercialization of COMP360 depends on market acceptance by healthcare providers, patients, and payers. The novelty of psilocybin-based treatments may present challenges in adoption and reimbursement.

Industry Context

The mental health therapeutics market is undergoing significant innovation, with a growing interest in novel treatment modalities beyond traditional pharmaceuticals. Biotechnology companies are exploring psychedelic compounds, like psilocybin, for their potential to offer rapid and durable responses for conditions with high unmet needs. However, the development pathway is complex, involving rigorous clinical trials, regulatory hurdles, and the need for new treatment paradigms and reimbursement models.

Regulatory Implications

COMPASS Pathways operates in a highly regulated environment. The company's development of COMP360, a psilocybin-based treatment, faces stringent FDA review processes. While Breakthrough Therapy designation for TRD is a positive signal, successful completion of Phase 3 trials and adherence to evolving regulatory standards for novel psychoactive substances are critical for eventual market approval.

What Investors Should Do

1. Monitor cash burn and future financing needs.
2. Evaluate Phase 3 trial progress and outcomes.
3. Assess the competitive landscape and market adoption potential.

Key Dates

• 2018-01-01: FDA Breakthrough Therapy Designation — Granted for COMP360 for the treatment of TRD, indicating potential for accelerated development and review.
• 2021-11-01: Positive Top-Line Phase 2b Results — Announced positive results from the Phase 2b clinical trial for COMP360 in TRD, supporting further development.
• 2022-11-03: Phase 2b Results Published in NEJM — Publication in a leading medical journal validated the efficacy and safety findings of the Phase 2b trial, enhancing credibility.
• 2025-06-01: COMP005 Trial Achieved Primary Endpoint — The first pivotal Phase 3 trial for COMP360 in TRD met its primary endpoint, a critical milestone for regulatory approval.
• 2025-01-01: Completion of Phase 3 Enrollment — Enrollment completed for both pivotal Phase 3 trials (COMP005 with 258 patients and COMP006 with 581 patients) for TRD, advancing the program towards completion.

Glossary

COMP360

COMPASS Pathways' proprietary psilocybin formulation, optimized for stability and purity, being developed as a treatment for serious mental health conditions. (This is the company's lead investigational drug candidate and the focus of its clinical development efforts.)

Treatment-Resistant Depression (TRD)

A subset of major depressive disorder where patients do not respond adequately to at least two different antidepressant treatments. (TRD is the primary indication COMPASS Pathways is targeting with COMP360, representing a significant unmet medical need.)

Breakthrough Therapy Designation

A designation granted by the FDA to a drug that is intended, alone or in combination with one or more other drugs, to treat a serious or life-threatening disease or condition, and preliminary clinical evidence indicates that the drug may demonstrate substantial improvement over existing therapies. (This designation for COMP360 in TRD suggests potential for expedited review and development, but does not guarantee approval.)

Pivotal Trial

A clinical trial that is designed to provide the primary evidence of a drug's efficacy and safety for regulatory approval. (The company's COMP005 and COMP006 trials are pivotal trials, meaning their successful completion is essential for seeking FDA approval for COMP360.)

Montgomery-Åsberg Depression Rating Scale (MADRS)

A widely used scale to measure the severity of depressive symptoms in patients. (This is the primary endpoint measure for COMPASS Pathways' pivotal Phase 3 trials, indicating how the drug's effectiveness is being assessed.)

Year-Over-Year Comparison

The company continues to operate without revenue, consistent with its pre-commercial stage. The primary development in the past year has been the completion of enrollment for its two pivotal Phase 3 trials (COMP005 and COMP006) for TRD, a significant step forward. The COMP005 trial has also reported achieving its primary endpoint. New risks related to the ongoing clinical development and the substantial capital required for these advanced trials remain prominent, alongside the inherent uncertainties of drug development and regulatory approval.

Key Financial Figures

• $100.0 million — , to draw down additional amounts up to $100.0 million in accordance with the terms of our Loa

Filing Documents

• cmps-20251231.htm (10-K) — 2362KB
• pwcconsent2025-ex231xus.htm (EX-23.1) — 2KB
• pwcconsent2025-ex232xuk.htm (EX-23.2) — 2KB
• cmps-10xkxex311ceo302certi.htm (EX-31.1) — 10KB
• cmps-10xkxex312cfo302certi.htm (EX-31.2) — 10KB
• cmps-10xkxex321ceoxcfosect.htm (EX-32.1) — 9KB
• cmps-20251231_g1.jpg (GRAPHIC) — 114KB
• cmps-20251231_g2.jpg (GRAPHIC) — 82KB
• cmps-20251231_g3.jpg (GRAPHIC) — 67KB
• cmps-20251231_g4.jpg (GRAPHIC) — 52KB
• cmps-20251231_g5.jpg (GRAPHIC) — 61KB
• cmps-20251231_g6.jpg (GRAPHIC) — 57KB
• 0001816590-26-000020.txt ( ) — 10617KB
• cmps-20251231.xsd (EX-101.SCH) — 62KB
• cmps-20251231_cal.xml (EX-101.CAL) — 98KB
• cmps-20251231_def.xml (EX-101.DEF) — 323KB
• cmps-20251231_lab.xml (EX-101.LAB) — 755KB
• cmps-20251231_pre.xml (EX-101.PRE) — 582KB
• cmps-20251231_htm.xml (XML) — 950KB

Business

Business 8 Item 1A.

Risk Factors

Risk Factors 51 Item 1B. Unresolved Staff Comments 170 Item 1C. Cybersecurity 170 Item 2.

Properties

Properties 171 Item 3.

Legal Proceedings

Legal Proceedings 171 Item 4. Mine Safety Disclosures 171 PART II Item 5. Market for Registrant's Common Equity, Related Stockholder Matters and Issuer Purchases of Equity Securities 172 Item 6. [Reserved] 172 Item 7.

Management's Discussion and Analysis of Financial Condition and Results of Operations

Management's Discussion and Analysis of Financial Condition and Results of Operations 173 Item 7A.

Quantitative and Qualitative Disclosures About Market Risk

Quantitative and Qualitative Disclosures About Market Risk 188 Item 8.

Financial Statements and Supplementary Data

Financial Statements and Supplementary Data 189 Item 9. Changes in and Disagreements with Accountants on Accounting and Financial Disclosure 189 Item 9A.

Controls and Procedures

Controls and Procedures 189 Item 9B. Other Information 190 Item 9C. Disclosure Regarding Foreign Jurisdictions that Prevent Inspections 199 PART III Item 10. Directors, Executive Officers and Corporate Governance 200 Item 11.

Executive Compensation

Executive Compensation 200 Item 12.

Security Ownership of Certain Beneficial Owners and Management and Related Stockholder Matters

Security Ownership of Certain Beneficial Owners and Management and Related Stockholder Matters 200 Item 13. Certain Relationships and Related Transactions, and Director Independence 200 Item 14. Principal Accountant Fees and Services 200 PART IV Item 15. Exhibit and Financial Statement Schedules 201 Item 16. Form 10-K Summary 204

Signatures

Signatures F- 31 2 Table of Contents SPECIAL NOTE REGARDING FORWARD-LOOKING STATEMENTS This Annual Report on Form 10-K includes forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, or the "Securities Act," and Section 21E of the Securities Exchange Act of 1934, as amended, or the "Exchange Act". Forward-looking statements generally relate to future events or our future financial or operating performance. All statements other than statements of historical fact included in this Annual Report on Form 10-K, including regarding our strategy, future operations, financial position, estimated revenues and losses, projected costs, prospects, plans and objectives of management, are forward-looking statements. In some cases, you can identify forward-looking statements because they contain words such as "may," "will," "should," "expects," "plans," "anticipates," "could," "intends," "target," "projects," "contemplates," "believes," "estimates," "predicts," "potential" or "continue" or the negative of these words or other similar terms or expressions. The forward-looking statements and opinions contained in this Form 10-K are based upon information available to our management as of the date of this Form 10-K, and while we believe such information forms a reasonable basis for such statements, such information may be limited or incomplete, and our statements should not be read to indicate that we have conducted an exhaustive inquiry into, or review of, all potentially available relevant information. Forward-looking statements contained in this Annual Report on Form 10-K include, but are not limited to, statements about: the timing, progress and results of our Phase 3 program for treatment-resistant depression, or TRD, and our other clinical trials of investigational COMP360 psilocybin treatment, including statements regarding the preliminary results to date from our two ongoing Phase 3 trials for TRD, the timing of initiat

BUSINESS

ITEM 1. BUSINESS Overview We are a biotechnology company dedicated to accelerating patient access to evidence-based innovation in mental health. We are motivated by the need to find better ways to help and empower people with serious mental health conditions who are not helped by existing treatments. We are pioneering a new paradigm for treating mental health conditions focused on rapid and durable responses through the development of our investigational COMP360 psilocybin treatment, potentially a first in class treatment. COMP360 is our proprietary psilocybin formulation that includes our pharmaceutical-grade polymorphic crystalline psilocybin, optimized for stability and purity. We believe that our COMP360 psilocybin treatment could offer a new approach to treatment of serious mental health conditions, including treatment-resistant depression, or TRD, which is a subset of major depressive disorder, or MDD, post-traumatic stress disorder, or PTSD, and potentially many other serious mental health conditions . Our initial focus is on TRD, comprising patients who are inadequately served by current treatment options. In 2018, we received Breakthrough Therapy designation from the U.S. Food and Drug Administration, or the FDA, for COMP360 for the treatment of TRD. In November 2021, we announced positive top-line results from our Phase 2b clinical trial evaluating COMP360 for the treatment of TRD. On November 3, 2022, The New England Journal of Medicine published the positive results from our Phase 2b trial. This is the largest, randomized, controlled, double-blind psilocybin treatment clinical trial completed to date. The objective of the Phase 2b study was to evaluate the efficacy and safety of a single dose of investigational COMP360 psilocybin (25mg or 10mg), compared to 1mg, in patients with TRD. The trial achieved its primary endpoint for the 25mg dose, with a 25mg dose of COMP360 demonstrating a statistically significant and clinically relevant treatment differ

View Full Filing

View this 10-K filing on SEC EDGAR